JOHNSON & JOHNSON is 87.9x more valuable than Spyre Therapeutics, Inc. by market capitalization ($573.98 B vs $6.53 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SYRE | JNJ |
|---|---|---|
| Market cap | $6.53 B | $573.98 B |
| US-listed rank | #1200 | #20 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$155.20M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 762 | 984 |
JOHNSON & JOHNSON is 87.9x more valuable than Spyre Therapeutics, Inc. by market capitalization ($573.98 B vs $6.53 B).
In their latest fiscal years, Spyre Therapeutics, Inc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Spyre Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.